MAPT (Tau) Expression is a Biomarker for an Increased Rate of Survival in Pediatric Neuroblastoma

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2018 Nov 6

PMID 30394813

Citations 15

Authors

Saif Zaman

Boris I Chobrutskiy

George Blanck

Affiliations

Soon will be listed here.

Abstract

Although the impact of MAPT (Tau) expression has been well documented for neuronal cells in the context of tauopathies and neurodegenerative diseases, the impact and role of Tau expression in cancer, and specifically cancers of neuronal origin, is in its infancy. To determine the correlation between MAPT expression and survival in pediatric neuroblastoma, MAPT gene expression for samples from the TARGET pediatric neuroblastoma dataset was assessed. Initial analyses indicated that increased MAPT expression correlated with increased overall survival in neuroblastoma but not in ovarian cancer. Expression of apoptosis- and proliferation-effector genes in the neuroblastoma samples was consistent with the MAPT related survival result. Furthermore, we determined that higher neuroblastoma expression of APP also associated with neurodegeneration, correlated with better neuroblastoma survival rates. In sum, Gene expression associated with neuronal degenerative diseases was associated with a better neuroblastoma outcome. Abbreviations: ALS: Amyotrophic Lateral Sclerosis; APP: Amyloid Precursor Protein gene; CASP3: Caspase 3 gene; CASP9: Caspase 9 gene; H2AFX: H2A histone family, member X gene; HIST1H2AL: Histone H2A type 1 gene; HIST1H2BK: Histone H2B type 1-K gene; HIST1H3J: Histone H3J gene; HIST1H4B: Histone H4B gene; HIST2H2BE: Histone H2B type 2-E gene; HUGO: human genome organization; KM: Kaplan-Meier survival curve; MAPT: Tau gene; OV: Ovarian cancer; SNCA: alpha-syneculin gene; TARDBP: Transactive response DNA binding protein 43 kDa; TCGA: the cancer genome atlas.

Citing Articles

Decoding TDP-43: the molecular chameleon of neurodegenerative diseases.

Zeng J, Luo C, Jiang Y, Hu T, Lin B, Xie Y Acta Neuropathol Commun. 2024; 12(1):205.

PMID: 39736783 PMC: 11687198. DOI: 10.1186/s40478-024-01914-9.

Implications of TDP-43 in non-neuronal systems.

Ke H, Liu K, Jiao B, Zhao L Cell Commun Signal. 2023; 21(1):338.

PMID: 37996849 PMC: 10666381. DOI: 10.1186/s12964-023-01336-5.

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response.

Callari M, Sola M, Magrin C, Rinaldi A, Bolis M, Paganetti P Sci Data. 2023; 10(1):637.

PMID: 37730697 PMC: 10511431. DOI: 10.1038/s41597-023-02543-y.

Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma.

Yan Z, Liu Q, Cao Z, Wang J, Zhang H, Liu J Front Neuroinform. 2022; 16:1034793.

PMID: 36439943 PMC: 9687102. DOI: 10.3389/fninf.2022.1034793.

A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.

Ma K, Zhang P, Xia Y, Dong L, Li Y, Liu L BMC Med Genomics. 2022; 15(1):242.

PMID: 36419120 PMC: 9685875. DOI: 10.1186/s12920-022-01400-y.

References

Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C . Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis. 2017; 38(10):1011-1020. DOI: 10.1093/carcin/bgx077. View

Cheng J, Hiemstra J, Schneider S, Naumova A, Cheung N, Cohn S . Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet. 1993; 4(2):191-4. DOI: 10.1038/ng0693-191. View

Gervais F, Xu D, Robertson G, Vaillancourt J, Zhu Y, Huang J . Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999; 97(3):395-406. DOI: 10.1016/s0092-8674(00)80748-5. View

Emanuel B, Balaban G, Boyd J, Grossman A, Negishi M, Parmiter A . N-myc amplification in multiple homogeneously staining regions in two human neuroblastomas. Proc Natl Acad Sci U S A. 1985; 82(11):3736-40. PMC: 397862. DOI: 10.1073/pnas.82.11.3736. View

Choi S, Oh J, Kim H, Nam S, Shin J, Park J . Protective Effect of Tat PTD-Hsp27 Fusion Protein on Tau Hyperphosphorylation Induced by Okadaic Acid in the Human Neuroblastoma Cell Line SH-SY5Y. Cell Mol Neurobiol. 2015; 35(7):1049-59. PMC: 4572059. DOI: 10.1007/s10571-015-0199-1. View

Petroni D, Tsai J, Agrawal K, Mondal D, George W . Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Environ Toxicol. 2011; 27(9):549-55. DOI: 10.1002/tox.20672. View

Akinrinmade O, Jordaan S, Hristodorov D, Mladenov R, Mungra N, Chetty S . Human MAP Tau Based Targeted Cytolytic Fusion Proteins. Biomedicines. 2017; 5(3). PMC: 5618294. DOI: 10.3390/biomedicines5030036. View

Arnal I, Wade R . How does taxol stabilize microtubules?. Curr Biol. 1995; 5(8):900-8. DOI: 10.1016/s0960-9822(95)00180-1. View

Louis C, Shohet J . Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2014; 66:49-63. PMC: 4418018. DOI: 10.1146/annurev-med-011514-023121. View

10.

Floris G, Borghero G, Cannas A, Stefano F, Murru M, Corongiu D . Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. J Neurol. 2014; 262(2):375-84. DOI: 10.1007/s00415-014-7575-5. View

11.

Schiff P, Fant J, Horwitz S . Promotion of microtubule assembly in vitro by taxol. Nature. 1979; 277(5698):665-7. DOI: 10.1038/277665a0. View

12.

Jazvinscak Jembrek M, Hof P, Simic G . Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation. Oxid Med Cell Longev. 2015; 2015:346783. PMC: 4458271. DOI: 10.1155/2015/346783. View

13.

Mielke M, Haughey N, Bandaru V, Zetterberg H, Blennow K, Andreasson U . Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiol Aging. 2014; 35(11):2486-2494. PMC: 4170854. DOI: 10.1016/j.neurobiolaging.2014.05.019. View

14.

Spillantini M, Goedert M . Tau pathology and neurodegeneration. Lancet Neurol. 2013; 12(6):609-22. DOI: 10.1016/S1474-4422(13)70090-5. View

15.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

16.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

17.

Wiernik P, Schwartz E, Strauman J, Dutcher J, Lipton R, Paietta E . Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987; 47(9):2486-93. View

18.

Monroy-Ramirez H, Basurto-Islas G, Mena R, Cisneros B, Binder L, Avila J . Alterations in the nuclear architecture produced by the overexpression of tau protein in neuroblastoma cells. J Alzheimers Dis. 2013; 36(3):503-20. DOI: 10.3233/JAD-122401. View

19.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J . The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010; 12(3):R43. PMC: 2917038. DOI: 10.1186/bcr2598. View

20.

Lee M, McGeer E, McGeer P . Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Neurobiol Aging. 2014; 36(1):42-52. DOI: 10.1016/j.neurobiolaging.2014.07.024. View